|
Malignant neoplasm of breast
|
0.330 |
AlteredExpression
|
disease |
BEFREE |
Hence, we believe that targeting key protein rRNA methyltransferase FBL shows great potential, due to its pivotal role in ribosome biogenesis, its correlation to an improved survival rate at low expression in breast cancer patients and its association with p53.
|
30501594 |
2019 |
|
Breast Carcinoma
|
0.330 |
AlteredExpression
|
disease |
BEFREE |
Hence, we believe that targeting key protein rRNA methyltransferase FBL shows great potential, due to its pivotal role in ribosome biogenesis, its correlation to an improved survival rate at low expression in breast cancer patients and its association with p53.
|
30501594 |
2019 |
|
Malignant neoplasm of breast
|
0.330 |
AlteredExpression
|
disease |
BEFREE |
We report that snoRNAs and fibrillarin (FBL, an enzymatic small nucleolar ribonucleoprotein, snoRNP) are frequently overexpressed in both murine and human breast cancer as well as in prostate cancers, and significantly, that this overexpression is essential for tumorigenicity in vitro and in vivo.
|
23542174 |
2014 |
|
Breast Carcinoma
|
0.330 |
AlteredExpression
|
disease |
BEFREE |
We report that snoRNAs and fibrillarin (FBL, an enzymatic small nucleolar ribonucleoprotein, snoRNP) are frequently overexpressed in both murine and human breast cancer as well as in prostate cancers, and significantly, that this overexpression is essential for tumorigenicity in vitro and in vivo.
|
23542174 |
2014 |
|
Malignant neoplasm of breast
|
0.330 |
AlteredExpression
|
disease |
BEFREE |
FBL overexpression contributes to tumorigenesis and is associated with poor survival in patients with breast cancer.
|
24029231 |
2013 |
|
Breast Carcinoma
|
0.330 |
AlteredExpression
|
disease |
BEFREE |
FBL overexpression contributes to tumorigenesis and is associated with poor survival in patients with breast cancer.
|
24029231 |
2013 |
|
Malignant neoplasm of breast
|
0.330 |
Biomarker
|
disease |
CTD_human |
An integrative approach to identify YB-1-interacting proteins required for cisplatin resistance in MCF7 and MDA-MB-231 breast cancer cells.
|
21466612 |
2011 |
|
Breast Carcinoma
|
0.330 |
Biomarker
|
disease |
CTD_human |
An integrative approach to identify YB-1-interacting proteins required for cisplatin resistance in MCF7 and MDA-MB-231 breast cancer cells.
|
21466612 |
2011 |
|
Autoimmune Diseases
|
0.310 |
Biomarker
|
group |
CTD_human |
Treatment with gold in the form of aurothiomaleate, silver or mercury (Hg) in genetically susceptible mouse strains (H-2(s)) induces a systemic autoimmune condition characterized by anti-nuclear antibodies targeting the 34-kDa nucleolar protein fibrillarin, as well as lymphoproliferation and systemic immune-complex (IC) deposits.
|
19077085 |
2009 |
|
Autoimmune Diseases
|
0.310 |
Biomarker
|
group |
CTD_human |
The genotype determines the B cell response in mercury-treated mice.
|
9693280 |
1998 |
|
Autoimmune Diseases
|
0.310 |
Biomarker
|
group |
CTD_human |
Murine genotype influences the specificity, magnitude and persistence of murine mercury-induced autoimmunity.
|
8738957 |
1996 |
|
Autoimmune Diseases
|
0.310 |
AlteredExpression
|
group |
BEFREE |
Human fibrillarin expressed in vitro migrates on SDS gels as a 36-kDa protein that is specifically immunoprecipitated by antisera from humans with scleroderma autoimmune disease.
|
1846968 |
1991 |
|
Adenocarcinoma of lung (disorder)
|
0.300 |
Biomarker
|
disease |
CTD_human |
c-Myc targeted regulators of cell metabolism in a transgenic mouse model of papillary lung adenocarcinoma.
|
27602772 |
2016 |
|
Mammary Neoplasms, Human
|
0.300 |
Biomarker
|
disease |
CTD_human |
An integrative approach to identify YB-1-interacting proteins required for cisplatin resistance in MCF7 and MDA-MB-231 breast cancer cells.
|
21466612 |
2011 |
|
Mammary Neoplasms
|
0.300 |
Biomarker
|
group |
CTD_human |
An integrative approach to identify YB-1-interacting proteins required for cisplatin resistance in MCF7 and MDA-MB-231 breast cancer cells.
|
21466612 |
2011 |
|
Mammary Carcinoma, Human
|
0.300 |
Biomarker
|
disease |
CTD_human |
An integrative approach to identify YB-1-interacting proteins required for cisplatin resistance in MCF7 and MDA-MB-231 breast cancer cells.
|
21466612 |
2011 |
|
Hepatitis C
|
0.100 |
Biomarker
|
disease |
BEFREE |
LDH was significantly associated with advanced liver fibrosis (FIB-4 aOR = 22.22 [1.22-403.72]) only among HIV/HCV+ participants with an LDH of 100-600 kg.
|
31812989 |
2020 |
|
Liver Cirrhosis
|
0.100 |
Biomarker
|
disease |
BEFREE |
The AUROCs of TE using M and XL probes, SWE, APRI, and FIB-4 were 0.771, 0.761, 0.700, 0.698, and 0.697 respectively, for significant fibrosis; 0.974, 0.973, 0.929, 0.738, and 0.859, respectively, for advanced fibrosis; and 0.954, 0.949, 0.962, 0.765, and 0.962, respectively, for cirrhosis.
|
31799740 |
2020 |
|
Liver Cirrhosis
|
0.100 |
Biomarker
|
disease |
BEFREE |
VCTE demonstrated excellent diagnostic accuracy for the detection of cirrhosis with an AUROC of 0.90 compared with APRI (0.83), FIB-4 (0.88), AAR (0.73) and RPR (0.85).
|
31742822 |
2020 |
|
Liver Cirrhosis
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
A larger reduction was observed in persons with more advanced fibrosis/cirrhosis (absolute difference 2.9 for FIB-4<1.25; 5.7 for FIB-4 1.26-3.25; 9.8 for FIB-4>3.25).
|
30977808 |
2020 |
|
Liver Cirrhosis
|
0.100 |
Biomarker
|
disease |
BEFREE |
The fibrosis score 4 (FIB-4) has been identified as a biochemical surrogate for histological fibrogenesis and fibrosis in cirrhosis.
|
31167732 |
2020 |
|
Liver Cirrhosis
|
0.100 |
Biomarker
|
disease |
BEFREE |
The risk of HCC was the highest in patients who had persistently high FIB-4/APRI and both with and without cirrhosis.
|
31222774 |
2020 |
|
Liver diseases
|
0.100 |
GeneticVariation
|
group |
BEFREE |
Advanced markers of liver disease were most strongly associated with hazardous drinking (≥40(women)/60(men) grams/day) (APRI aOR = 15.87 (3.22-78.12); FIB-4 aOR = 6.76 (1.81-7.16)) and PEth ≥400 ng/ml (APRI aOR = 17.52 (2.55-120.54); FIB-4 aOR = 17.75 (3.30-95.630).
|
31812989 |
2020 |
|
Fibrosis, Liver
|
0.100 |
Biomarker
|
disease |
BEFREE |
LDH was significantly associated with advanced liver fibrosis (FIB-4 aOR = 22.22 [1.22-403.72]) only among HIV/HCV+ participants with an LDH of 100-600 kg.
|
31812989 |
2020 |
|
Fibrosis, Liver
|
0.100 |
Biomarker
|
disease |
BEFREE |
Liver fibrosis was assessed using the fibrosis-4 index (FIB-4) [age (years)× aspartate aminotransferase level (IU/L)/platelet count (10<sup>9</sup>/L)/√alanine aminotransferase (IU/L)].
|
30557057 |
2020 |